Trident Lifeline

Why is Trident Lifeline Ltd falling/rising?

As of 11-Jun, Trident Lifeline Ltd's stock price is at 241.15, down 3.04%, marking a trend reversal after five days of gains. The stock has declined 11.11% over the past month and 22.38% year-to-date, with bearish sentiment reflected in its trading below key moving averages and a drop in investor participation.

As of 11-Jun, Trident Lifeline Ltd's stock price is falling, currently at 241.15, which reflects a decrease of 7.55 or 3.04%. The stock has underperformed its sector by 3.46% today and has experienced a trend reversal, falling after five consecutive days of gains. It touched an intraday low of Rs 240, which is 3.5% lower than its previous close. <BR><BR>The stock's performance over the past month shows a significant decline of 11.11%, while year-to-date, it has fallen by 22.38%. This downward trend is further supported by the fact that the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment among investors. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by 24.46% compared to the 5-day average.<BR><BR>Despite some positive factors, such as a strong ability to service debt and healthy long-term growth in net sales and operating profit, the recent flat results and a significant drop in profit before tax (PBT) of 62.2% compared to the previous four-quarter average have raised concerns. Moreover, the reduction in promoter confidence, as indicated by a 1.26% decrease in their stake, suggests a lack of faith in the company's future prospects, contributing to the stock's decline.

What does Trident Lifeline do?

Trident Lifeline Ltd markets ethical pharmaceutical products and operates in the Pharmaceuticals & Biotechnology industry as a Micro Cap company. As of December 2025, it reported net sales of 26 Cr and a net profit of 4 Cr, with a market cap of INR 294 Cr.

Overview: <BR>Trident Lifeline Ltd is engaged in the marketing of ethical pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>Trident Lifeline Ltd was originally incorporated as a Private Limited Company on January 09, 2014. It converted to a Public Limited Company following a Shareholders' Resolution on June 02, 2022, and subsequently changed its name to "Trident Lifeline Limited" on June 10, 2022. The most recent quarterly results reported net sales and net profit for December 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 26 Cr (Quarterly Results - Dec 2025) <BR>Net Profit: 4 Cr (Quarterly Results - Dec 2025) <BR>Market Cap: INR 294 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.68 <BR>Return on Equity: 19.30% <BR>Price to Book: 2.93 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Which are the latest news on Trident Lifeline?

How big is Trident Lifeline?

As of 10th June, Trident Lifeline Ltd has a market capitalization of 294.00 Cr, with recent net sales of 114.67 Cr and a net profit of 19.38 Cr. Shareholder's funds are 64.46 Cr, and total assets amount to 153.60 Cr.

As of 10th June, Trident Lifeline Ltd has a market capitalization of 294.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Trident Lifeline reported Net Sales of 114.67 Cr and a Net Profit of 19.38 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 64.46 Cr and Total Assets of 153.60 Cr.

Who are in the management team of Trident Lifeline?

The management team of Trident Lifeline includes Hardik J Desai (Chairman & Executive Director), Mayurkumar Mansukhbhai Gajera (Whole Time Director & CFO), Shravan Harikrishna Patel (Managing Director), Maniya H Desai (Non-Executive Director), Aena Surana (Independent Director), Mishal Shailesh Patel (Independent Director), and Jiteshkumar Ramchandra Varkal (Company Secretary & Compliance Officer).

The management team of Trident Lifeline includes the following individuals:<BR><BR>1. Hardik J Desai - Chairman & Executive Director<BR>2. Mayurkumar Mansukhbhai Gajera - Whole Time Director & CFO<BR>3. Shravan Harikrishna Patel - Managing Director<BR>4. Maniya H Desai - Non-Executive Director<BR>5. Aena Surana - Independent Director<BR>6. Mishal Shailesh Patel - Independent Director<BR>7. Jiteshkumar Ramchandra Varkal - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Trident Lifeline?

Trident Lifeline's peers include Valiant Laborato, Medico Remedies, Transchem, and others, with varying management risks and growth rates. Transchem leads in 1-year returns at 605.82%, while Valiant Laborato has the lowest at -40.70%, and Trident Lifeline's return is -7.81%.

Peers: The peers of Trident Lifeline are Valiant Laborato, Medico Remedies, Transchem, Medicamen Biotec, Zenotech Lab., Astonea Labs, Gennex Lab., Ambalal Sarabhai, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medico Remedies and Sat Kartar, while Average management risk is found at Transchem, Medicamen Biotec, Zenotech Lab., Astonea Labs, Gennex Lab., and the rest. Below Average management risk is noted for Valiant Laborato, Ambalal Sarabhai, and Infinium Pharma. Growth is Excellent at Trident Lifeline, Good at Medico Remedies, Valiant Laborato, Zenotech Lab., Astonea Labs, Gennex Lab., and the rest, while Below Average growth is seen at Transchem, Medicamen Biotec, Ambalal Sarabhai, and Infinium Pharma. Capital Structure is Excellent at Medicamen Biotec, Zenotech Lab., and Gennex Lab., Good at Trident Lifeline and Medico Remedies, Below Average at Valiant Laborato and Astonea Labs, and Average at Ambalal Sarabhai.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Transchem at 605.82%, while the lowest is Valiant Laborato at -40.70%. Trident Lifeline's 1-year return of -7.81% is better than Valiant Laborato but worse than Transchem. Additionally, the six-month return is negative for Valiant Laborato, Medicamen Biotec, Gennex Lab., and Infinium Pharma.

Should I buy, sell or hold Trident Lifeline Ltd?

Are Trident Lifeline Ltd latest results good or bad?

Trident Lifeline Ltd's latest results show strong revenue growth of 117.33% year-on-year, reaching ₹25.71 crores, but profitability has declined, with net profit down 13.13% to ₹4.30 crores and operating margins compressed to 19.80%. Investors should be cautious due to concerns over earnings quality and reliance on non-operating income.

Trident Lifeline Ltd's latest results present a mixed picture. On the positive side, the company achieved impressive revenue growth, with net sales increasing by 117.33% year-on-year to ₹25.71 crores in Q3 FY26. This indicates strong market traction and the ability to scale operations effectively.<BR><BR>However, there are significant concerns regarding profitability. The consolidated net profit for the quarter declined by 13.13% quarter-on-quarter to ₹4.30 crores, down from ₹4.95 crores in the previous quarter. Additionally, the operating margin has compressed to 19.80%, a substantial drop from 25.08% in Q4 FY25. This margin erosion raises questions about the sustainability of earnings, especially given that a staggering 76.91% of profit before tax came from other income, highlighting a reliance on non-operating sources.<BR><BR>Overall, while the revenue growth is commendable, the decline in profitability and the quality of earnings are concerning. Investors should approach the situation with caution, monitoring future quarters for signs of margin recovery and reduced dependency on other income.

When is the next results date for Trident Lifeline Ltd?

The next results date for Trident Lifeline Ltd is 07 May 2026.

The next results date for Trident Lifeline Ltd is scheduled for 07 May 2026.

How has been the historical performance of Trident Lifeline?

Trident Lifeline has shown significant growth in net sales, operating income, and profitability from Mar'22 to Mar'25, with net sales increasing from 21.77 Cr to 86.96 Cr and profit after tax rising from 3.95 Cr to 10.49 Cr. However, cash flow from operations has declined, with a cash outflow of 10.00 Cr in Mar'25.

Answer:<BR>The historical performance of Trident Lifeline shows significant growth in various financial metrics over the past four years.<BR><BR>Breakdown:<BR>Trident Lifeline's net sales have increased dramatically from 21.77 Cr in Mar'22 to 86.96 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 21.77 Cr to 86.96 Cr during the same period. The company's total expenditure also grew, from 19.06 Cr in Mar'22 to 72.11 Cr in Mar'25, driven by higher raw material costs and employee expenses. Operating profit (PBDIT) saw a substantial increase, reaching 23.08 Cr in Mar'25, up from just 3.31 Cr in Mar'22. Profit before tax rose from 2.98 Cr in Mar'22 to 13.61 Cr in Mar'25, while profit after tax increased from 3.95 Cr to 10.49 Cr in the same timeframe. The earnings per share (EPS) improved significantly from 4.94 in Mar'22 to 10.22 in Mar'25. On the balance sheet, total assets grew from 12.80 Cr in Mar'22 to 153.60 Cr in Mar'25, with total liabilities also increasing from 12.80 Cr to 153.60 Cr. Cash flow from operating activities showed a negative trend, with a cash outflow of 10.00 Cr in Mar'25 compared to a positive inflow of 2.00 Cr in Mar'24. Overall, Trident Lifeline has demonstrated robust growth in sales and profitability, although cash flow from operations has been challenging in recent years.

How has been the historical performance of Trident Lifeline?

Trident Lifeline has shown significant growth over the past four years, with net sales increasing from 21.77 Cr in Mar'22 to 86.96 Cr in Mar'25, and profit after tax rising from 3.95 Cr to 10.49 Cr. However, cash flow from operating activities has been negative, indicating challenges despite overall revenue and profitability growth.

Answer:<BR>The historical performance of Trident Lifeline shows significant growth in various financial metrics over the past four years.<BR><BR>Breakdown:<BR>Trident Lifeline's net sales have increased from 21.77 Cr in Mar'22 to 86.96 Cr in Mar'25, reflecting a strong upward trend. Total operating income has followed a similar trajectory, rising from 21.77 Cr to 86.96 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, from 19.06 Cr in Mar'22 to 72.11 Cr in Mar'25. Operating profit (PBDIT) has improved markedly, from 3.31 Cr in Mar'22 to 23.08 Cr in Mar'25, although the operating profit margin has slightly decreased from 12.45% to 17.08%. Profit before tax has risen from 2.98 Cr to 13.61 Cr, leading to a profit after tax increase from 3.95 Cr to 10.49 Cr. The consolidated net profit has also shown growth, moving from 3.95 Cr in Mar'22 to 11.75 Cr in Mar'25. On the balance sheet, total assets have surged from 12.80 Cr to 153.60 Cr, while total liabilities have increased from 12.80 Cr to 153.60 Cr as well, indicating a proportional rise in both assets and liabilities. Cash flow from operating activities has been negative in recent years, with a cash outflow of 10.00 Cr in Mar'25, despite a positive cash flow from financing activities of 19.00 Cr. Overall, Trident Lifeline has demonstrated robust growth in revenue and profitability, alongside increasing liabilities and assets.

Is Trident Lifeline overvalued or undervalued?

As of October 30, 2025, Trident Lifeline is considered very expensive with a PE ratio of 23.10 and an EV to EBIT ratio of 24.99, indicating overvaluation compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 13.93%.

As of 30 October 2025, Trident Lifeline's valuation grade has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued, with a PE ratio of 23.10, an EV to EBIT ratio of 24.99, and a Price to Book Value of 5.98. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Trident Lifeline's valuation stands out, particularly against Sun Pharma Industries, which has a PE ratio of 35.63, and Cipla, which is valued attractively at a PE of 22.87. The PEG ratio of 0.28 for Trident Lifeline further emphasizes its overvaluation, especially when compared to Divi's Lab's PEG of 2.03. Notably, Trident Lifeline has outperformed the Sensex over various periods, including a 13.93% return year-to-date, which may reflect investor optimism despite the high valuation metrics.

Who are the top shareholders of the Trident Lifeline?

The top shareholders of Trident Lifeline include Hardik Jigishkumar Desai with 23.5%, foreign institutional investors holding 6.62%, and Nav Capital Vcc - Nav Capital Emerging Star Fund with 6.01%. Individual investors own 18.26%, while no mutual funds hold shares in the company.

The top shareholders of Trident Lifeline include the promoters, who hold the majority of the shares. The promoter with the highest holding is Hardik Jigishkumar Desai, who owns 23.5% of the company. Additionally, foreign institutional investors (FIIs) hold 6.62% of the shares through three different entities. The highest public shareholder is Nav Capital Vcc - Nav Capital Emerging Star Fund, which holds 6.01%. Individual investors collectively own 18.26% of the company. There are no mutual funds currently holding shares in Trident Lifeline.

What is the technical trend for Trident Lifeline?

As of June 6, 2025, Trident Lifeline's trend is mildly bullish due to a bullish MACD and Bollinger Bands, despite some mixed signals from daily moving averages and other indicators.

As of 6 June 2025, the technical trend for Trident Lifeline has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are also bullish, indicating positive momentum. However, the daily moving averages remain mildly bearish, which suggests some short-term weakness. The weekly KST is bearish, and the Dow Theory indicates a mildly bearish stance on the weekly timeframe, adding caution to the overall outlook. The RSI shows no signals on both weekly and monthly timeframes. Overall, the current stance is mildly bullish, driven primarily by the bullish MACD and Bollinger Bands, despite some mixed signals from other indicators.

Has Trident Lifeline declared dividend?

No Dividend History Available